Cardiff Oncology Raises $10M at Premium, Insiders Join Offering
CRDF is trading near its 52-week low of $0.83 (6.0% above the low) on elevated volume (9.1× avg).
Summary
Cardiff Oncology raised $10.05 million in a registered direct offering at $1.05 per share, a 19% premium to its $0.88 stock price, signaling strong institutional demand. Insiders added 721,649 shares at $1.455 with matching warrants, demonstrating conviction. The company engaged H.C. Wainwright as placement agent. This follows a going-concern warning and a short cash runway disclosed in May; the capital extends the runway as the company advances onvansertib after positive Phase 2 data in June. The premium pricing and insider participation are notable given the recent license dispute and financial strain.
At the time of this announcement, CRDF was trading at $0.88 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $60.8M. The 52-week trading range was $0.83 to $4.56. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.